Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease.

ABSTRACT:

Background and objectives

Revefenacin is a lung-selective, long-acting muscarinic antagonist indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease. The objectives of this analysis were to evaluate the pharmacokinetics of revefenacin and its major metabolite (THRX-195518) in patients with chronic obstructive pulmonary disease, and identify significant covariates affecting revefenacin disposition using a population pharmacokinetic approach based on plasma concentration-time data obtained after single- and repeated-dose once-daily administration in three phase II and two phase III studies.

Methods

Plasma concentrations of revefenacin and THRX-195518 following once-daily administration via nebulization at a dose levels ranging from 22-700

SUBMITTER: Lo A 

PROVIDER: S-EPMC7932972 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature